ENTA Overview

JP Morgan Coverage Initiation: On November 14, 2025, JP Morgan began coverage of Enanta Pharmaceuticals (NasdaqGS:ENTA) with an "Overweight" recommendation, projecting a 62.04% upside based on an average one-year price target of $19.53/share.

Projected Revenue and EPS: Enanta Pharmaceuticals is expected to see a significant increase in annual revenue, projected at $834 million, which represents a 1,186.29% growth, alongside a projected non-GAAP EPS of 10.27.

Institutional Ownership Trends: There are currently 275 funds reporting positions in Enanta Pharmaceuticals, with a slight increase in ownership and a total of 20,591K shares held by institutions, reflecting a 1.16% rise over the last three months.

Shareholder Activity: Notable changes in shareholder positions include Janus Henderson Group increasing its stake by 111.20%, while Millennium Management reduced its holdings by 53.85%, indicating varied strategies among institutional investors.

Analyst Ratings Overview: Top Wall Street analysts have updated their ratings on several companies, including Microsoft, Enanta Pharmaceuticals, and Polaris Inc.

Microsoft Corp Rating: Baird analyst William Power initiated coverage on Microsoft with an Outperform rating and a price target of $600, while shares closed at $503.29.

Enanta Pharmaceuticals Rating: JP Morgan analyst Anupam Rama initiated coverage on Enanta Pharmaceuticals with an Overweight rating and a price target of $17, with shares closing at $11.72.

Polaris Inc Rating: Loop Capital analyst Brandon Rolle initiated coverage on Polaris with a Hold rating and a price target of $59, while shares closed at $64.82.

Stock Performance: Enanta Pharmaceuticals' shares rose after J.P. Morgan initiated coverage with an Overweight rating, highlighting the potential of their experimental RSV therapy, zelicapavir.

Analyst Projections: Analyst Anupam Rama set a price target of $17 per share, forecasting over $1.5 billion in peak global sales for zelicapavir, with significant contributions expected from the U.S. market.

Clinical Trial Success: The stock's surge followed positive mid-stage trial results for zelicapavir, which is designed for high-risk outpatient adults with acute RSV, indicating strong market potential.

Partnership Opportunities: Enanta is likely to seek partnerships for zelicapavir, which could lead to substantial non-dilutive financing, with peak net global revenue estimates exceeding $300 million.

Zelicapavir's Efficacy in Pediatric Patients: New data presented at IDWeek™ 2025 indicates that zelicapavir significantly shortens the duration of RSV symptoms in children aged 28 days to 36 months, with a median resolution time of 6.99 days compared to 8.60 days for placebo.

EDP-323's Potential in Prophylaxis: EDP-323 has shown high effectiveness in preventing RSV infection when administered post-exposure, with a study revealing that none of the participants receiving EDP-323 became infected, compared to 26% in the placebo group.

Public Offering Closure: Enanta Pharmaceuticals has successfully closed its public offering of approximately 7.48 million shares.

Financial Implications: The completion of this offering may impact the company's financial position and future growth strategies.